Business Wire

IL-ISACA

Share
ISACA Offers New Certification for Upskilling and Cross-skilling in Emerging Technologies

Emerging technologies are essential to digital transformation and business progress—whether it is blockchain used in supply chains and in the financial industry or artificial intelligence in driving efficiency across sectors. IT professionals seeking to boost their skillset in emerging technologies and ensure their knowledge is up to date can now pursue the Certified in Emerging Technology (CET) certification from global IT professional association and learning organization ISACA.

Established IT professionals, students and recent grads alike can set themselves apart with employers and gain foundational knowledge about the Internet of Things (IoT), artificial intelligence (AI), blockchain and cloud without having prior experience. Along with the recently launched ISACA credential, the Information Technology Certified Associate (ITCA) , the CET certification is unique in offering a vendor-agnostic, hybrid learning model. The CET model features both performance-based and knowledge-based learning—including live labs in a virtual environment—and incorporates a stackable series of certificates.

These certificates, which can be achieved at one’s own pace from anywhere, provide both an examination of each technology and a holistic view of the connections among the emerging technologies, allowing IT professionals to upskill and cross-skill in the following domains:

  • Cloud Fundamentals Certificate
  • Blockchain Fundamentals Certificate
  • IoT Fundamentals Certificate
  • Artificial Intelligence Fundamentals Certificate

“It is important for professionals in IT audit, risk, security, governance and privacy to have an understanding of emerging technologies and how they intersect with their work, as well as impact their organizations at a business level,” says David Samuelson, ISACA CEO. “With the new Certified in Emerging Technology certification, ISACA is pleased to offer our global community the tools to gain this knowledge and skillset and continue to take their careers to new heights.”

The CET certification is a good fit for professionals at different levels and job functions—from students and recent graduates wanting to build their résumés, to those already established in roles in governance, risk and compliance; IT audit; network administration; software development; information security; enterprise architecture and business management who want to learn more about emerging technology and how it applies to their roles and organizations.

“Continual up-skilling is a strong signal of professionalism in all IT fields,” said Caitlin McGaw, Principal, Candor McGaw. “Hiring managers are actively looking for people with emerging technology skills. However, since companies are still ramping up these technologies, many professionals have not yet had the chance to gain that experience. Being able to demonstrate the accomplishment of high-quality training and hands-on work with emerging technology will be a substantial competitive advantage for experienced professionals and recent grads alike.”

The CET certification program offers study guides, self-paced training courses, virtual instructor-led training, additional lab packages and exams for each certificate, available at discounted rates to ISACA members. Custom training packages for up-skilling IT teams are also available. Once all four certificate exams are completed, the CET certification is awarded.

This new certification joins an established set of ISACA credentials that have been part of the professional community’s learning journey for years, including Certified Information Systems Auditor (CISA), Certified Information Security Manager (CISM), Certified in Risk and Information Systems Control (CRISC), Certified in the Governance of Enterprise IT (CGEIT), CSX Cybersecurity Practitioner Certification (CSX-P), Certified Data Privacy Solutions Engineer (CDPSE) and ITCA certification.

For more information about the CET certification, visit www.isaca.org/credentialing/cet . More detail about ISACA’s other credentials can be found at www.isaca.org/credentialing , and ISACA publications, audit programs and other resources on emerging tech, including the recently published blockchain framework, are available at www.isaca.org/resources/emerging-technology-resources .

About ISACA

For more than 50 years, ISACA® (www.isaca.org ) equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. ISACA is a global professional association and learning organization with more than 150,000 members who work in information security, governance, assurance, risk and privacy, and a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.

Twitter: www.twitter.com/ISACANews
LinkedIn: www.linkedin.com/company/isaca
Facebook: www.facebook.com/ISACAGlobal
Instagram: www.instagram.com/isacanews

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 13:05:00 CEST | Press release

Q-Alliance launch marks a key milestone in Italy’s digital transformation and the country’s ambitious quantum ecosystem goals IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transf

Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 12:01:00 CEST | Press release

Reliable, Quiet Single-Tower Air Coolers Built on Patented 3DHP Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 12:00:00 CEST | Press release

New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show promise in advanced solid tumors BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will b

SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 11:00:00 CEST | Press release

SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock

New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK20.10.2025 10:01:00 CEST | Press release

For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye